Gilead Rival Shoots To Two-Year High On Hepatitis D News

Vir Biotechnology's hepatitis delta treatment met Phase III goals, with 79% of patients virus-free at week 48. The trial showed 85% efficacy in patients with cirrhosis. No serious adverse events were reported. Vir plans to submit data to the FDA in mid-2027. The company expects top-line results from ECLIPSE 2 and 3 trials in Q1 2027.

Vir Biotechnology's combination of elebsiran and tobevibart met primary endpoints in Phase II and III trials for chronic hepatitis delta, with 44% of patients achieving undetectable virus and ALT normalization at week 48. The treatment was well-tolerated. According to the company, the results position the therapy as a potential best-in-disease treatment.

Vir Biotechnology's combination of elebsiran and tobevibart met the primary endpoint in the ECLIPSE 1 trial, with 44% of patients achieving undetectable HDV RNA and ALT normalization at week 48, compared to 0% in the delayed-treatment arm. The company plans to submit a global regulatory package, and Norgine holds exclusive rights for Europe, Australia, and New Zealand.

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

Vir Biotechnology reported positive results from a Phase 3 trial of its hepatitis D drug combination, elebsiran and tobevibart, meeting primary and secondary endpoints. The treatment achieved a 44% response rate in 48 weeks, with 79% of patients showing reduced viral levels. Vir plans to submit regulatory data in 2027 if further trials succeed. Hepatitis D affects 5% of chronic hepatitis B cases globally, with limited current treatments. Analysts predict the drug could become a leading therapy.

Vir Biotechnology (VIR) shares rose 13.92% to $13.91 after reporting Phase 2 trial data showing 100% of patients achieved undetectable hepatitis delta virus levels. 89% of patients showed improved or stable liver stiffness. The stock's 52-week range is $5.22 to $14.38, with volume at 4.08 million shares. The company plans a Phase 3 ECLIPSE program with a 2027 regulatory filing.